FeesSafety
Pluang+

Investigation launched into Concentrix over alleged securities fraud after earnings warnings and goodwill impairments.

Market News
29 Oct 2026, 16:40 WIB
PRNewsWire
View Source
Bearish
Investigation launched into Concentrix over alleged securities fraud after earnings warnings and goodwill impairments.

Pomerantz LLP is investigating Concentrix Corporation and some of its officers for possible securities fraud following the company's lowered revenue and earnings forecasts and a significant $1.05 billion goodwill impairment disclosed in 2026. The stock price dropped sharply after these announcements, raising concerns among investors. The investigation aims to determine if Concentrix engaged in unlawful business practices, with potential class action participation available for affected investors. This could lead to legal consequences and financial repercussions for the company and its leadership.

Concentrix Corporation is the subject of an investor investigation, and for readers following the Technology sector, here is Pluang's market snapshot as of Oct 29, 2026 20:41 WIB: Out of 150 priced US technology stocks, only 19 rose while 129 fell. Among notable movers, Mondaycom Ltd (MNDY) dropped 6.75% to USD 91.22 with a typical hold time of 17 days, Teradyne, Inc. (TER) fell 6.56% to USD 292.70 with a balanced buy-sell order activity (48% Sell / 52% Buy) and a longer hold time of 38 days, while Fastly Inc (FSLY) declined 6.22% to USD 25.35 with a dominant 97% sell order activity and a 26-day hold time.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
54 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
54 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App